Field: Technology

A simple supplement may help clear brain fog after cancer

Published | Technical Staff

A simple supplement may help clear brain fog after cancer

Visualization

In the intricate tapestry of cancer treatment, the fight against the disease is only part of the battle; for many survivors, the cognitive aftermath can prove as formidable as the disease itself. A recent investigation spearheaded by researchers at the University of California, Los Angeles (UCLA) offers a glimmer of hope, suggesting that oxaloacetate, a naturally occurring metabolite, may alleviate some of the cognitive impairments often dubbed "chemo brain." This study, published in JCO Oncology Advances, reveals tantalizing evidence of oxaloacetate’s potential to combat lingering cognitive deficits experienced by breast cancer survivors.

Cancer-related cognitive impairment, defined as a spectrum of cognitive difficulties that arise during or after cancer treatment, affects a significant subset of patients. Statistics reveal that approximately 15% to 25% of breast cancer survivors grapple with enduring issues related to memory, concentration, and executive function long after their oncological therapies conclude. These symptoms stem from a complex interplay of factors—chemotherapy, endocrine therapies, hormonal fluctuations, and neuroinflammation—all contributing to a disruption in normal cognitive processes.

Oxaloacetate caught the attention of the UCLA researchers due in part to its pivotal role in energy production and neurotransmitter regulation within the brain. It serves as a key substrate in the tricarboxylic acid (TCA) cycle, a fundamental metabolic pathway crucial for ATP synthesis. Moreover, its involvement in modulating glutamate, the primary excitatory neurotransmitter in the central nervous system, positions it as a promising candidate for restoring cognitive function compromised by cancer and its treatments.

To rigorously evaluate the efficacy of oxaloacetate supplementation, the research team orchestrated a phase II clinical trial including 18 female participants who had been diagnosed with early-stage breast cancer. These women, averaging around 50 years in age, had undergone various therapeutic regimens including chemotherapy and were generally within one to five years post-diagnosis. Each participant received a precise dosage of 500 milligrams of oxaloacetate, administered bi-daily for a period of eight weeks. Their cognitive impairments were meticulously monitored through a battery of standardized assessments focused on memory, attention, processing speed, and executive function—critical mental capabilities essential for everyday functioning.

Remarkably, the participants reported significant cognitive improvements post-treatment. The mean score on perceived cognitive impairment jumped from 29.1 to a normalizing 55.5, indicating a restoration of cognitive function. This apparent enhancement in cognitive performance was substantiated by results from the cognitive assessments, showing not just subjective improvement but objective gains in processing speed and executive function—parameters crucial for efficient task management and mental clarity.

Interestingly, participants experienced notable reductions in fatigue, including the debilitating mental exhaustion that often complicates daily activities for cancer survivors. Enhanced physical functionality was also reported, suggesting that oxaloacetate may yield comprehensive benefits that transcend cognitive capabilities.

While these results are promising, the researchers exercise caution, noting the small sample size and the lack of a control group. The findings remain preliminary, and further studies will be essential to firmly establish oxaloacetate's efficacy as a therapeutic intervention for cancer-related cognitive deficits. Gastrointestinal side effects were the most frequently reported adverse events, yet the overall tolerability profile was favorable, with no serious complications reported throughout the trial.

In response to these early but encouraging results, UCLA is poised to conduct a larger, randomized, placebo-controlled phase II trial to further investigate the cognitive benefits of oxaloacetate supplementation in breast cancer survivors. This forthcoming study aims to substantiate the initial findings and provides a robust framework for understanding the extent of oxaloacetate's effects on cognitive recovery.

As scientific inquiry propels forward, the convergence of metabolic biochemistry and cognitive rehabilitation may yield innovative avenues for assisting breast cancer survivors. The interactions between inflammation, neurotransmitter signaling, and energy metabolism after cancer treatment present an intricate landscape ripe for exploration. Ultimately, studies like this one illuminate not just the delicate recovery of cognitive function following cancer treatments, but the multifaceted approaches required to genuinely improve the quality of life for survivors.